Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Serogroup B meningococci cause the majority of the meningococcal disease burden in developed countries. Production of an effective and safe vaccine for serogroup B organisms has been hampered by the poor immunogenicity of the capsular polysaccharide that defines this group of bacteria. Previous efforts have focused on outer membrane vesicle vaccines, which have been implemented successfully during clonal outbreaks. However, the search for a universal vaccine against endemic polyclonal serogroup B meningococcal disease continues. In this review, we have highlighted recent development of outer membrane vesicle vaccines and progress in the evaluation of recombinant outer membrane protein vaccines.

Original publication

DOI

10.1586/erv.09.30

Type

Journal article

Journal

Expert Rev Vaccines

Publication Date

06/2009

Volume

8

Pages

729 - 745

Keywords

Biomedical Research, Humans, Meningitis, Meningococcal, Meningococcal Vaccines, Neisseria meningitidis, Serogroup B, Secretory Vesicles